News coverage about Viking Therapeutics (NASDAQ:VKTX) has trended somewhat positive recently, according to Accern. The research group identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Viking Therapeutics earned a media sentiment score of 0.02 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 46.4595995037418 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s rankings:
VKTX has been the topic of several research reports. William Blair initiated coverage on shares of Viking Therapeutics in a research note on Monday, April 30th. They issued an “outperform” rating on the stock. ValuEngine upgraded shares of Viking Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 23rd. HC Wainwright set a $11.00 price objective on shares of Viking Therapeutics and gave the company a “buy” rating in a research note on Thursday, May 10th. Roth Capital upped their price objective on shares of Viking Therapeutics from $7.50 to $13.00 and gave the company a “buy” rating in a research note on Friday, June 1st. Finally, Laidlaw upped their price objective on shares of Viking Therapeutics from $10.00 to $15.00 and gave the company a “buy” rating in a research note on Friday, June 1st. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $14.25.
Viking Therapeutics stock opened at $12.74 on Friday. The company has a market capitalization of $587.26 million, a price-to-earnings ratio of -16.13 and a beta of 2.77. Viking Therapeutics has a twelve month low of $0.88 and a twelve month high of $12.92.
Viking Therapeutics (NASDAQ:VKTX) last released its quarterly earnings data on Wednesday, May 9th. The biotechnology company reported ($0.10) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.12) by $0.02. equities research analysts expect that Viking Therapeutics will post -0.45 earnings per share for the current year.
In other news, VP Michael Morneau sold 21,551 shares of the stock in a transaction on Thursday, May 31st. The shares were sold at an average price of $9.25, for a total transaction of $199,346.75. Following the transaction, the vice president now owns 94,035 shares in the company, valued at approximately $869,823.75. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director J Matthew Singleton purchased 9,500 shares of the company’s stock in a transaction dated Thursday, May 31st. The shares were acquired at an average price of $9.82 per share, for a total transaction of $93,290.00. Following the purchase, the director now owns 9,500 shares in the company, valued at $93,290. The disclosure for this purchase can be found here. 3.90% of the stock is currently owned by corporate insiders.
About Viking Therapeutics
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures.
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.